% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hemminki:170244,
      author       = {K. Hemminki$^*$ and A. Försti$^*$ and R. Houlston and A.
                      Sud},
      title        = {{E}pidemiology, genetics and treatment of multiple myeloma
                      and precursor diseases.},
      journal      = {International journal of cancer},
      volume       = {149},
      number       = {12},
      issn         = {1097-0215},
      address      = {Bognor Regis},
      publisher    = {Wiley-Liss},
      reportid     = {DKFZ-2021-01852},
      pages        = {1980-1996},
      year         = {2021},
      note         = {2021 Dec 15;149(12):1980-1996},
      abstract     = {Multiple myeloma (MM) is a hematological malignancy caused
                      by the clonal expansion of plasma cells. The incidence of MM
                      worldwide is increasing with greater than 140,000 people
                      being diagnosed with MM per year. While 5-year survival
                      following a diagnosis of MM has improved from $28\%$ in 1975
                      to $56\%$ in 2012 the disease remains essentially incurable.
                      In this review we summarize our current understanding of MM
                      including its epidemiology, genetics and biology. We will
                      also provide an overview of MM management that have led to
                      improvements in survival, including recent changes to
                      diagnosis and therapies. Areas of unmet need include the
                      management of patients with high-risk MM, those with a
                      reduced performance status and those refractory to standard
                      therapies. Ongoing research into the biology and early
                      detection of MM as well as the development of novel
                      therapies such as immunotherapies have the potential to
                      influence MM practice in the future. This article is
                      protected by copyright. All rights reserved.},
      subtyp        = {Review Article},
      keywords     = {clinical presentation (Other) / plasma cell disease (Other)
                      / risks factors (Other) / survival (Other) / treatment
                      (Other)},
      cin          = {B062 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:34398972},
      doi          = {10.1002/ijc.33762},
      url          = {https://inrepo02.dkfz.de/record/170244},
}